{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T06:27:26Z","timestamp":1761719246817},"reference-count":18,"publisher":"Scientific Scholar","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"Abstract<\/jats:title>\n \n Introduction:<\/jats:title>\n COVID-19, caused by SARS-CoV-2, has resulted in significant mortality and morbidity worldwide. Patients of chronic kidney disease who are on maintenance hemodialysis represent a vulnerable population cohort that is susceptible to severe disease. Hence, it is of utmost importance to prioritize vaccination in this population and to assess their response to said vaccination.<\/jats:p>\n <\/jats:sec>\n \n Methods:<\/jats:title>\n This prospective analytical study was conducted at the Institute of Nephrology, Madras Medical College, between August 2021 and February 2022. Patients of chronic kidney disease stage 5 dialysis (CKD5D) who were on maintenance hemodialysis and who consented to receive COVID-19 vaccine were studied. Serum samples were obtained before vaccination, \u226528 days after receiving the first dose of the vaccine, and \u226528 days after receiving the second dose. Antibody titers against the spike protein were estimated using the Roche chemiluminescent immunosorbent assay. Patients were grouped into non-responders\/seronegative (<0.8 U\/ml) and responders\/seropositive (\u22650.8 U\/ml), with a value \u2265250 U\/ml considered as robust response.<\/jats:p>\n <\/jats:sec>\n \n Results:<\/jats:title>\n A total of 96 patients were included. The mean age was 36.70 (\u00b111.53) years and 77.1% of them were male. The median dialysis vintage was 2 (IQR: 0.95\u20135) years. Twelve patients (9.9%) had a prior COVID-19 infection. Sixty-seven (69.8%) patients had received Covaxin and 29 (30.2%) had received Covishield vaccines. Among the 17 patients who were seronegative at baseline, 4 (23.52%) became seropositive after the first dose of the vaccine, and 11 (64.7%) were seropositive after the second dose, with high titers (\u201crobust response\u201d) achieved in two patients (11.76%). No antibody response, despite two doses of the vaccine, was noted in six patients (35.29%).<\/jats:p>\n <\/jats:sec>\n \n Conclusion:<\/jats:title>\n Our study showed a high baseline seropositivity rate, even prior to vaccination, which indicated a high rate of subclinical COVID infection. Among those who were seronegative at baseline, the seroconversion rate after two doses of Covaxin or Covishield was 64.70%.<\/jats:p>\n <\/jats:sec>","DOI":"10.4103\/ijn.ijn_7_23","type":"journal-article","created":{"date-parts":[[2023,8,7]],"date-time":"2023-08-07T11:07:05Z","timestamp":1691406425000},"source":"Crossref","is-referenced-by-count":1,"title":["SARS-CoV-2 Antibody Seroprevalence and Humoral Response to Vaccination in Patients Undergoing Maintenance Hemodialysis: A Prospective Cohort Study"],"prefix":"10.25259","author":[{"given":"Guhan","family":"Senthilkumaran","sequence":"first","affiliation":[{"name":"Institute of Nephrology, Madras Medical College, Chennai, Tamil Nadu, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vaishanavi D.","family":"Rajarathinam","sequence":"additional","affiliation":[{"name":"Institute of Nephrology, Madras Medical College, Chennai, Tamil Nadu, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Srinivasaraman","family":"Govindarajan","sequence":"additional","affiliation":[{"name":"Radiologist, Anderson Diagnostics and Labs, Chennai, Tamil Nadu, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V. S.","family":"Jibia","sequence":"additional","affiliation":[{"name":"Institute of Nephrology, Madras Medical College, Chennai, Tamil Nadu, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chelvamalai M.","family":"Balasubramanian","sequence":"additional","affiliation":[{"name":"Institute of Nephrology, Madras Medical College, Chennai, Tamil Nadu, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prem K.","family":"Devaraju","sequence":"additional","affiliation":[{"name":"Institute of Nephrology, Madras Medical College, Chennai, Tamil Nadu, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vinoj","family":"Murugesan","sequence":"additional","affiliation":[{"name":"Institute of Nephrology, Madras Medical College, Chennai, Tamil Nadu, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P","family":"Shankar","sequence":"additional","affiliation":[{"name":"Institute of Nephrology, Madras Medical College, Chennai, Tamil Nadu, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tanuj M.","family":"Lamech","sequence":"additional","affiliation":[{"name":"Institute of Nephrology, Madras Medical College, Chennai, Tamil Nadu, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Venkatesh","family":"Arumugam","sequence":"additional","affiliation":[{"name":"Institute of Nephrology, Madras Medical College, Chennai, Tamil Nadu, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natarajan","family":"Gopalakrishnan","sequence":"additional","affiliation":[{"name":"Institute of Nephrology, Madras Medical College, Chennai, Tamil Nadu, India"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10894","published-online":{"date-parts":[[2023,8,4]]},"reference":[{"key":"R1-20230807","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1016\/j.kint.2020.07.030","article-title":"Outcomes of patients with end-stage kidney disease hospitalized with COVID-19","volume":"98","author":"Ng","year":"2020","journal-title":"Kidney Int"},{"key":"R2-20230807","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1093\/ndt\/gfaa261","article-title":"COVID- 19-related mortality in kidney transplant and dialysis patients: Results of the ERACODA collaboration","volume":"35","author":"Hilbrands","year":"2020","journal-title":"Nephrol Dial Transplant"},{"key":"R3-20230807","doi-asserted-by":"crossref","first-page":"n997","DOI":"10.1136\/bmj.n997","article-title":"What do we know about India's Covaxin vaccine?","volume":"373","author":"Thiagarajan","year":"2021","journal-title":"BMJ"},{"key":"R4-20230807","first-page":"191","article-title":"Applications of nanotechnology in vaccine development for coronavirus (SARS-CoV-2) disease (Covid-19)","volume":"8","author":"Malabadi","year":"2021","journal-title":"Int J Res Sci Inno"},{"key":"R6-20230807","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","article-title":"Safety and efficacy of the ChAdOx1 NCoV-19 vaccine (AZD1222) against SARS-CoV-2: An interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK","volume":"397","author":"Voysey","year":"2021","journal-title":"Lancet"},{"key":"R7-20230807","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1016\/S0140-6736(21)02000-6","article-title":"Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): Interim results of a randomised, double-blind, controlled, phase 3 trial","volume":"398","author":"Ella","year":"2021","journal-title":"Lancet"},{"key":"R8-20230807","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1007\/s40620-021-01072-4","article-title":"A clinical study on the changing dynamics of disease severity, management strategies and outcomes of COVID-19 in patients requiring haemodialysis","volume":"34","author":"Nithya","year":"2021","journal-title":"J Nephrol"},{"key":"R9-20230807","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/j.kint.2020.09.006","article-title":"Results from the ERA-EDTA Registry indicate a high mortality due to COVID-19 in dialysis patients and kidney transplant recipients across Europe","volume":"98","author":"Jager","year":"2020","journal-title":"Kidney Int"},{"key":"R10-20230807","doi-asserted-by":"crossref","first-page":"E278","DOI":"10.1503\/cmaj.202601","article-title":"COVID-19 in patients undergoing long-term dialysis in Ontario","volume":"193","author":"Taji","year":"2021","journal-title":"CMAJ"},{"key":"R11-20230807","doi-asserted-by":"crossref","first-page":"439","DOI":"10.3390\/toxins12070439","article-title":"Immune dysfunction in uremia 2020","volume":"12","author":"Cohen","year":"2020","journal-title":"Toxins"},{"key":"R12-20230807","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1016\/j.ekir.2021.06.027","article-title":"Review of early immune response to SARS-CoV-2 vaccination among patients with CKD","volume":"6","author":"Carr","year":"2021","journal-title":"Kidney Int Rep"},{"key":"R13-20230807","doi-asserted-by":"crossref","first-page":"3208","DOI":"10.1681\/ASN.2021070908","article-title":"Predictors and dynamics of the humoral and cellular immune response to SARS-CoV-2 mRNA vaccines in hemodialysis patients: A multicenter observational study","volume":"32","author":"Van Praet","year":"2021","journal-title":"J Am Soc Nephrol"},{"key":"R14-20230807","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1053\/j.ajkd.2021.06.002","article-title":"Humoral and cellular responses to mRNA-1273 and BNT162b2 SARS-CoV-2 vaccines administered to hemodialysis patients","volume":"78","author":"Broseta","year":"2021","journal-title":"Am J Kidney Dis Off J Natl Kidney Found"},{"key":"R15-20230807","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.1681\/ASN.2021050611","article-title":"Antibody response to COVID-19 vaccination in patients receiving dialysis","volume":"32","author":"Anand","year":"2021","journal-title":"J Am Soc Nephrol JASN"},{"key":"R16-20230807","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1681\/ASN.2020060827","article-title":"High prevalence of asymptomatic COVID-19 infection in hemodialysis patients detected using serologic screening","volume":"31","author":"Clarke","year":"2020","journal-title":"J Am Soc Nephrol"},{"key":"R17-20230807","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1056\/NEJMp2211314","article-title":"A Covid-19 milestone attained-A correlate of protection for vaccines","volume":"387","author":"Gilbert","year":"2022","journal-title":"N Engl J Med"},{"key":"R18-20230807","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1016\/j.kint.2021.10.006","article-title":"Waning humoral response 6 months after SARS-COV-2 vaccination with mRNA BNT162b2 vaccine in hemodialysis patients: Time for a boost","volume":"100","author":"Davidovic","year":"2021","journal-title":"Kidney Int"},{"key":"R19-20230807","doi-asserted-by":"crossref","first-page":"e84","DOI":"10.1056\/NEJMoa2114583","article-title":"Waning immune humoral response to BNT162b2 Covid-19 vaccine over 6 months","volume":"385","author":"Levine","year":"2021","journal-title":"N Engl J Med"}],"container-title":["Indian Journal of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.4103\/ijn.ijn_7_23","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,3]],"date-time":"2024-04-03T19:49:13Z","timestamp":1712173753000},"score":1,"resource":{"primary":{"URL":"https:\/\/indianjnephrol.org\/sars-cov-2-antibody-seroprevalence-and-humoral-response-to-vaccination-in-patients-undergoing-maintenance-hemodialysis-a-prospective-cohort-study\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,4]]},"references-count":18,"URL":"https:\/\/doi.org\/10.4103\/ijn.ijn_7_23","relation":{},"ISSN":["0971-4065","1998-3662"],"issn-type":[{"value":"0971-4065","type":"print"},{"value":"1998-3662","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,4]]}}}